Uptake of macromolecules
First Claim
Patent Images
1. A solid pharmaceutical composition comprising a mixture of:
- (a) an active macromolecular principle which is a polypeptide or protein, polynucleotide or polysaccharide;
(b) a non-conjugated bile acid or salt; and
(c) an additive chosen from(i) propyl gallate or a linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio or C2-12 alkenyl ester of gallic acid which is optionally substituted with one or more groups which are the same or different and are selected from halogen and linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio or C2-12 alkenyl;
(ii) butyl hydroxy anisole, or hydroxy anisole wherein the methoxy group linked to the aromatic ring and/or the hydrogen ortho to the hydroxyl group is/are replaced by one or more groups which are the same or different and are selected from linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio and C2-12 alkenyl, either unsubstituted or substituted in any position by one or more halogen atoms; and
(iii) a mixture of (i) and (ii)wherein the mixture comprises at least 1% by weight of the additive (c), wherein the ratio by weight of the non-conjugated bile salt+additive (b+c) to the active macromolecular principle is at least 3;
1 and wherein the composition, when introduced into the intestine, does not raise the pH of the intestinal fluid above pH 7.0.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention provides a pharmaceutical composition comprising a mixture of: (a) an active macromolecular principle; and (b) a non-conjugated bile acid or salt; and (c) an additive chosen from propyl gallate, butyl hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof.
27 Citations
32 Claims
-
1. A solid pharmaceutical composition comprising a mixture of:
-
(a) an active macromolecular principle which is a polypeptide or protein, polynucleotide or polysaccharide; (b) a non-conjugated bile acid or salt; and (c) an additive chosen from (i) propyl gallate or a linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio or C2-12 alkenyl ester of gallic acid which is optionally substituted with one or more groups which are the same or different and are selected from halogen and linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio or C2-12 alkenyl; (ii) butyl hydroxy anisole, or hydroxy anisole wherein the methoxy group linked to the aromatic ring and/or the hydrogen ortho to the hydroxyl group is/are replaced by one or more groups which are the same or different and are selected from linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio and C2-12 alkenyl, either unsubstituted or substituted in any position by one or more halogen atoms; and (iii) a mixture of (i) and (ii) wherein the mixture comprises at least 1% by weight of the additive (c), wherein the ratio by weight of the non-conjugated bile salt+additive (b+c) to the active macromolecular principle is at least 3;
1 and wherein the composition, when introduced into the intestine, does not raise the pH of the intestinal fluid above pH 7.0.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
-
21. A method of enhancing the absorption of an active macromolecular principle which is polypeptide or protein, polynucleotide or polysaccharide across the intestinal wall in a human or animal body, which method comprises administering a non-conjugated bile acid or salt, together with an additive chosen from:
-
(i) propyl gallate or a linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio or C2-12 alkenyl ester of gallic acid which is optionally substituted with one or more groups which are the same or different and are selected from halogen and linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio or C2-12 alkenyl; (ii) butyl hydroxy anisole, or hydroxy anisole wherein the methoxy group linked to the aromatic ring and/or the hydrogen ortho to the hydroxyl group is/are replaced by one or more groups which are the same or different and are selected from linear or branched chain C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylthio and C2-12 alkenyl, either unsubstituted or substituted in any position by one or more halogen atoms; and (iii) a mixture of (i) and (ii) together with the active macromolecular principle in a solid pharmaceutical composition, wherein the additive accounts for at least 1% by weight of the total weight of (a) the active macromolecular principle, (b) the non-conjugated bile acid or salt, plus (c) the additive, wherein the ratio by weight of the non-conjugated bile salt+additive (b+c) to the active macromolecular principle is at least 3;
1 and wherein the composition, when introduced into the intestine, does not raise the pH of the intestinal fluid above pH 7.0, which method enhances the absorption of the active macromolecular principle due to the additive improving the solubility of the bile salt.- View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
Specification